Bristol-Myers Squibb (BMY)

The numbers don't tell the full story with this big pharma stock.

The market appears to be short-sighted.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them.

What happens when you actually do the thing most investors only talk about and hold stocks for a full decade?

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin...

This may be an excellent deal for those focused on the long game.

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independe

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

It scored crushing beats on both revenue and profitability in its first quarter.

Bristol Myers (BMY) Q1 2026 Earnings Transcript

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri...

It may not seem like it at first, but these dividends are safe.

This pharma stock is cheap for a reason.

Volatility and dividend yield are important metrics for investors thinking about a long-term buy.

As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Recent performances don't tell the whole story.

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66